Bayer (ETR:BAYN) announced that it is entering into a collaboration agreement with artificial intelligence drug discovery company Exscientia to identify and optimize novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases. The agreement, announced earlier this month, is slated to see the companies work together on early research projects combining Exscientia’s proprietary…
ASLS wins Frost & Sullivan bioprinting award
Advanced Solutions Life Sciences announced that it won the Frost & Sullivan 2019 Bioprinting Value Leadership Award for demonstrating best-in-class biofabrication, hardware, software and consulting services. Last month’s award highlights global consultancy firm Frost & Sullivan’s view that ASLS develops unique and cost-effective solutions to advance the development of life-saving drugs by way of 3D bioprinting,…
Dyve Biosciences hires new chief scientific officer
Transdermal drug therapy developer Dyve Biosciences announced that it appointed longtime Pfizer executive Chuck Harbert to the role of chief scientific officer. Harbert spent three decades at Pfizer, serving as the company’s VP of U.S. exploratory development and strategic planning, among other senior positions with Pfizer Central Research. He is the inventor and co-inventor of 35 pharmaceutical…
Dicerna and Novo Nordisk to develop RNAi therapies for liver-related cardio-metabolic diseases
Dicerna Pharmaceuticals (NSDQ:DRNA) announced today that it closed a discovery & development agreement with Novo Nordisk (NYSE:NVO) worth at least $175 million to further development of therapies for treating liver-related cardio-metabolic diseases. The two companies announced the agreement on Nov. 18, 2019, outlining the plan to discover and develop the therapies using Dicerna’s GalXC RNAi platform…
CEL-SCI prices $5.5m common stock offering
Phase 3 cancer immunotherapy company Cel-Sci (NYSE:CVM) announced today that it priced an underwritten public offering of common stock with expected gross proceeds of $5.5 million. Vienna, Va.–based Cel-Sci is offering 606,395 shares of common stock at a price of $9.07 per share to total the $5.5 million before deducting underwriting discounts and other estimated expenses. The…
Sanofi eyes Synthrox purchase
Sanofi (NYSE:SNY) announced today that it is planning to tender an offer to acquire all outstanding common stock shares of clinical-stage biotech company Synthorx. The agreement and plan of merger between the two companies was announced on Dec. 7 and the offer is being made pursuant to that. Sanofi said it stands to acquire the common…
Triplet Therapeutics launches with $59 million in funding
Biotechnology company Triplet Therapeutics announced that it launched earlier this week with $59 million in financing as it develops ways to treat certain types of genetic disorders at their source. The $59 million includes a $49 million Series A financing round led by MPM Capital and Pfizer Ventures U.S. Co-founder Atlas Venture seeded Triplet with…
Veristat acquires Catalyst Regulatory Services
Contract research organization Veristat announced today that it completed the acquisition of Catalyst Regulatory Services, a company that provides regulatory support to biopharmaceutical firms, for an undisclosed amount. Southborough, Mass.-based Veristat said Catalyst’s combination of experience and expertise in the regulatory space will help the company implement strategies, applications, submissions and interactions with regulatory agencies…
Propeller Health offers access to CVS, other pharmacies with Propeller app
Propeller Health announced today that users of its Propeller app are now able to access pharmacy services from CVS, Walmart, Kroger and Rite-Aid directly through that app. The Madison, Wis.–based company launched the app in January 2019, giving Walgreens patients the option to manage their asthma or chronic obstructive pulmonary disease medication regimen within the mobile app.…